Real-world Studies of CDK4/6 Inhibitors
Recruiting · NCT07407439 · Observational (researchers observe without assigning treatment) · Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
View the official record on ClinicalTrials.gov →What this trial is about
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥ 18 years old;
- Patients diagnosed with HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025;
- Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle;
- Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc.
Exclusion criteria
- Incomplete medical history data.
- Only received CDK4/6 inhibitors monotherapy.
- Received CDK4/6 inhibitors as neoadjuvant/postoperative adjuvant intensification therapy.
Where it is running
1 location listed.
- Tianjin Medical University Cancer Insititute and Hospital - Tianjin, China